全文获取类型
收费全文 | 2401篇 |
免费 | 199篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 99篇 |
妇产科学 | 45篇 |
基础医学 | 469篇 |
口腔科学 | 40篇 |
临床医学 | 234篇 |
内科学 | 340篇 |
皮肤病学 | 112篇 |
神经病学 | 267篇 |
特种医学 | 83篇 |
外科学 | 173篇 |
综合类 | 13篇 |
预防医学 | 201篇 |
眼科学 | 53篇 |
药学 | 239篇 |
中国医学 | 7篇 |
肿瘤学 | 225篇 |
出版年
2023年 | 26篇 |
2022年 | 33篇 |
2021年 | 93篇 |
2020年 | 83篇 |
2019年 | 94篇 |
2018年 | 114篇 |
2017年 | 86篇 |
2016年 | 85篇 |
2015年 | 94篇 |
2014年 | 104篇 |
2013年 | 148篇 |
2012年 | 222篇 |
2011年 | 217篇 |
2010年 | 138篇 |
2009年 | 101篇 |
2008年 | 167篇 |
2007年 | 179篇 |
2006年 | 128篇 |
2005年 | 142篇 |
2004年 | 90篇 |
2003年 | 87篇 |
2002年 | 83篇 |
2001年 | 11篇 |
2000年 | 11篇 |
1999年 | 10篇 |
1998年 | 11篇 |
1997年 | 9篇 |
1996年 | 3篇 |
1995年 | 10篇 |
1994年 | 2篇 |
1993年 | 6篇 |
1992年 | 1篇 |
1991年 | 2篇 |
1990年 | 1篇 |
1989年 | 2篇 |
1988年 | 3篇 |
1987年 | 2篇 |
1985年 | 2篇 |
1984年 | 2篇 |
1983年 | 2篇 |
1982年 | 2篇 |
1980年 | 2篇 |
1978年 | 2篇 |
1977年 | 1篇 |
1973年 | 1篇 |
1969年 | 1篇 |
排序方式: 共有2613条查询结果,搜索用时 31 毫秒
1.
Maja Popovic Gorana Matovina-Brko Masa Jovic Lazar S Popovic 《World journal of clinical oncology》2022,13(1):28-38
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with inter mediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozan tinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment. 相似文献
2.
3.
4.
Brandstetter Susanne Pawellek Maja Böhmer Merle M. Köninger Angela Melter Michael Kabesch Michael Apfelbacher Christian 《Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz》2022,65(12):1281-1288
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz - Mit Beginn der Impfkampagne hat eine neue Phase der Bewältigung der Coronapandemie begonnen. Zulassung und Empfehlung... 相似文献
5.
6.
7.
Haidar S. Dafsari Pablo Martinez‐Martin Alexandra Rizos Maja Trost Maria Gabriela dos Santos Ghilardi Prashanth Reddy Anna Sauerbier Jan Niklas Petry‐Schmelzer Milica Kramberger Robbert W. K. Borgemeester Michael T. Barbe Keyoumars Ashkan Monty Silverdale Julian Evans Per Odin Erich Talamoni Fonoff Gereon R. Fink Tove Henriksen Georg Ebersbach Zvezdan Pirtoek Veerle Visser‐Vandewalle Angelo Antonini Lars Timmermann K. Ray Chaudhuri 《Movement disorders》2019,34(3):353-365
8.
9.
Uterine,but not ovarian,female reproductive organ involvement at presentation by diffuse large B‐cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement 下载免费PDF全文
Tarec Christoffer El‐Galaly Chan Y. Cheah Martin Hutchings Nabegh George Mikhaeel Kerry J. Savage Laurie H. Sehn Sally Barrington Jakob W. Hansen Mette Ø. Poulsen Daniel Smith Kirsty Rady Karen J. Mylam Thomas S. Larsen Staffan Holmberg Maja B. Juul Sabrina Cordua Michael R. Clausen Kristina B. Jensen Martin Bøgsted Hans E. Johnsen John F. Seymour Joseph M. Connors Peter d. N. Brown Diego Villa 《British journal of haematology》2016,175(5):876-883
Involvement of the internal female reproductive organs by diffuse large B‐cell lymphoma (DLBCL) is uncommon, and there are sparse data describing the outcomes of such cases. In total, 678 female patients with DLBCL staged with positron emission tomography/computed tomography and treated with rituximab‐containing chemotherapy were identified from databases in Denmark, Great Britain, Australia, and Canada. Overall, 27/678 (4%) had internal reproductive organ involvement: uterus (n = 14), ovaries (n = 10) or both (n = 3). In multivariate analysis, women with uterine DLBCL experienced inferior progression‐free survival and overall survival compared to those without reproductive organ involvement, whereas ovarian DLBCL was not predictive of outcome. Secondary central nervous system (CNS) involvement (SCNS) occurred in 7/17 (41%) women with uterine DLBCL (two patients with concomitant ovarian DLBCL) and 0/10 women with ovarian DLBCL without concomitant uterine involvement. In multivariate analysis adjusted for other risk factors for SCNS, uterine involvement by DLBCL remained strongly associated with SCNS (Hazard ratio 14·13, 95% confidence interval 5·09–39·25, P < 0·001). Because involvement of the uterus by DLBCL appears to be associated with a high risk of SCNS, those patients should be considered for CNS staging and prophylaxis. However, more studies are needed to determine whether the increased risk of secondary CNS involvement also applies to women with localized reproductive organ DLBCL. 相似文献
10.
Maja Kodani Amanda Poe Jan Drobeniuc Tonya Mixson-Hayden 《Journal of medical virology》2020,92(12):3875-3879
Biotin taken orally can interfere with some diagnostic immunoassays, including those for thyroid hormones, ferritin, and markers of infectious disease. Assays affected are ones that use streptavidin-biotin in their design. The goal of our study was to examine the effect of biotin concentrations of up to 1200 ng/mL on three serological assays performed on VITROS 3600 system, Immunoglobulin M (IgM) antibodies to hepatitis A virus (anti-HAV), total anti-HAV, and IgM antibodies to hepatitis B virus core antigen (anti-HBc), by spiking serum samples with variable amounts of biotin. No false-negative results were generated with either concentration of biotin for total anti-HAV (65/65). Likewise, biotin caused no false-positive IgM anti-HAV results (59/59) with either concentration of biotin; however, 6.7% false negativity was found for IgM anti-HAV when samples were spiked with 1200 ng/mL of biotin. Conversely, 100% false positivity (30/30) was produced by biotin interference in total anti-HAV negative specimens with both concentrations of biotin. False negativity rate was 87.5% in IgM anti-HBc positive samples when biotin levels were at 1200 ng/mL. These data show that individuals taking biotin-containing supplements may test false-positive in some serologic assays using streptavidin-biotin chemistries. Further studies are warranted to determine the extent of biotin interference resulting in false-positive and negative results and their impact, if any, on surveillance and diagnostic settings. 相似文献